What is it?
What the human evidence answers
6A placebo-controlled healthy-volunteer study examined one 12.5 mg dose. It found changes in emotional processing but no effect on non-emotional cognition. That experimental result is different from better everyday memory, focus or mood. Clinical antidepressant research concerns a different population.
Names, aliases and forms
Mechanisms of action
Mu-opioid receptor activity
7Tianeptine activates mu-opioid receptors, proteins involved in opioid effects. Receptor and animal findings help explain its pharmacology but do not establish a cognitive benefit in people.
Potential effects and evidence map
Grade C: limited healthy-volunteer research includes a single-dose placebo-controlled study with emotional-processing changes but no improvement in non-emotional cognition. Prescription studies in depressed patients cannot establish healthy-user mood, memory or productivity benefits.
Acute emotional-processing findings are not evidence of improved everyday wellbeing in healthy users.
A single-dose healthy-volunteer study did not establish a practical attention benefit.
No improvement in non-emotional cognition was reported in the acute healthy-volunteer study.
Healthy-user stress resilience and sustained productivity benefits are not established.
Typical dosages and timing
The French sodium-tablet label describes this daily amount in divided doses for clinical use. It is not a validated healthy-adult nootropic dose or a conversion rule for sulfate, powders or blends.
Timing & effect horizon
In 12 healthy volunteers, oral tianeptine reached peak plasma concentration at about 0.94 hours and parent-drug The time for blood levels to fall by half during the final elimination phase.Source averaged 2.5 hours. The metabolite MC5 persisted longer. These measures do not define a useful nootropic onset, duration, redosing interval or safe cycle.
Safety, side effects and risk profile
As of October 2026, U.S. FDA does not approve tianeptine or recognize it as a dietary ingredient; prescription rules elsewhere differ.
Withdrawal is documented after prescription use; misuse and escalating doses can produce more severe dependence.
Irreversible MAO inhibitors carry potentially severe interaction risk. Alcohol and sedative combinations also need particular caution.
Sleep disruption can occur; severe agitation in poisoning or withdrawal is a separate context.
Serious cardiovascular and neurological effects occurred in an outbreak involving adulterated liquid products.
Healthy-user benefit, long-term use and equivalence across marketplace forms remain inadequately established.
Escalating doses and non-prescribed products have caused opioid-like toxicity and withdrawal. Breathing difficulty or unconsciousness is an emergency. A shorter plasma half-life is not a reason to redose or a guide to stopping dependence-producing use.
Interactions and cautions
The French label warns against irreversible MAO inhibitors and alcohol. FDA also reports serious harm in misuse involving other medicines, including antidepressants and anxiety medicines. Medication changes and withdrawal need clinical supervision; this page provides no combination or taper protocol.
Legal and regulatory status
As of October 15, 2026, U.S. FDA has not approved tianeptine for medical use and excludes it as a dietary ingredient. DEA's May 2026 fact sheet says it is not federally controlled under the Controlled Substances Act, while state controls differ. France retains prescription-only STABLON with special dispensing controls. Other countries have their own rules; a foreign listing does not establish permission to import.
Practical buying and quality notes
- These names describe different chemical forms. Record the exact form, strength per unit, release formulation and package count. Do not assume that a sulfate listing has clinically proven longer action or that equal milligram amounts are interchangeable with prescription sodium tablets.7
- The active TYNEPT title says tablets while the catalog classifies it as capsules. Read that as an unresolved format label, not evidence of capsule delivery or a dosing recommendation. Compare verified strength, units, shipping and local eligibility; package price alone cannot verify identity. Catalog correction remains pending.
- CDC investigated a 2023 New Jersey outbreak involving a branded tianeptine liquid; tested products contained synthetic cannabinoids. This does not prove every tianeptine product is adulterated. It does show why a label or seller purity claim cannot substitute for traceable manufacturer and batch-specific identity testing.3
FAQ
What is the nootropic dosage?
6No healthy-adult cognitive-enhancement regimen is established. The single-dose laboratory experiment and foreign prescription schedule answer different questions; neither validates self-directed long-term use.
How long does it last, and is cycling supported?
8The measured plasma half-life does not tell you how long a useful cognitive effect lasts. No validated nootropic cycling schedule was identified. Dependence and withdrawal make stop-start experimentation an unreliable safety strategy.
References
- FDA warns consumers not to purchase or use any tianeptine product due to serious risks. FDA. Content current as of May 8, 2025.
- FDA. Tianeptine in Dietary Supplements. Content current as of February 22, 2023.
- Notes from the Field: Cluster of Severe Illness from Neptune's Fix Tianeptine Linked to Synthetic Cannabinoids - New Jersey, June-November 2023. MMWR. 2024.
- Tianeptine, an Antidepressant with Opioid Agonist Effects: Pharmacology and Abuse Potential, a Narrative Review. Pain Ther. 2023.
- The Behavioral Effects of the Antidepressant Tianeptine Require the Mu-Opioid Receptor. Neuropsychopharmacology. 2017.
- Cooper CM et al. Tianeptine in an experimental medicine model of antidepressant action. Journal of Psychopharmacology. 2015.
- Drug Enforcement Administration Diversion Control Division. Tianeptine Drug Fact Sheet. May 2026.
- Salvadori C, Ward C, Defrance R, Hopkins R. The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans--influence of alcohol co-administration. Fundam Clin Pharmacol. 1990;4(1):115-125.
- ANSM / French public medicines database. STABLON 12.5 mg coated tablets: product characteristics (2019) and current prescription status, accessed October 15, 2026.